Clinical Guides
Autoimmune Hepatitis
A clinically focused guide to diagnosing and managing autoimmune hepatitis in India, including seronegative disease, biopsy, variant syndromes, pregnancy, difficult-to-treat disease and transplantation.
MedNext Academy | 13 min read
Autoimmune Hepatitis
A clinically focused guide to diagnosing and managing autoimmune hepatitis in India, including seronegative disease, biopsy, variant syndromes, pregnancy, difficult-to-treat disease and transplantation.
Summary
Autoimmune hepatitis (AIH) is an immune-mediated inflammatory liver disease that may present as incidental aminotransferase elevation, symptomatic chronic hepatitis, established cirrhosis, acute severe hepatitis or acute liver failure. It affects people of every age, sex and ethnicity. There is no single diagnostic marker. Diagnosis rests on a compatible pattern of hepatocellular injury, raised immunoglobulin G, characteristic autoantibodies, supportive liver histology and deliberate exclusion of viral, drug-related, metabolic, hereditary and cholestatic alternatives. A negative antibody panel does not end the assessment when the phenotype remains convincing.
Untreated active AIH can progress to fibrosis, decompensation, liver transplantation or death. The therapeutic goal is complete biochemical response, generally normalization of aminotransferases and IgG, followed by durable control with the least harmful immunosuppression. Glucocorticoids induce remission; a steroid-sparing agent supports maintenance. Treatment selection must account for cirrhosis, acute severity, cytopenia, pregnancy intentions, infection risk, thiopurine intolerance, access and adherence. Budesonide is not appropriate in cirrhosis and the 2025 EASL guideline no longer endorses it as routine first-line treatment.
AIH-primary biliary cholangitis and AIH-primary sclerosing cholangitis phenotypes require hepatology review, cholangiographic or serological evaluation and often biopsy because treating an assumed label can miss the dominant injury. Decompensation, acute liver failure or failure of correctly delivered immunosuppression should trigger transplant-centre discussion. This educational draft is has been reviewed by the MedNext Clinical Team, remains reviewed and cannot authorize diagnosis, immunosuppression, pregnancy decisions or transplantation.
How Common Is It?
AIH is uncommon but not geographically restricted. Reported incidence and prevalence vary because case definitions, antibody assays, biopsy practice, referral access and registry completeness differ. The 2026 Indian National Association for Study of the Liver guidance cites pooled global estimates of about 1.28 new cases per 100,000 person-years and prevalence around 15.65 per 100,000 people. These pooled figures describe studied populations, not a reliable census for any Indian state. Tertiary liver units see a higher proportion of acute severe disease, cirrhosis, overlap phenotypes and treatment failure than community practice.
Women are affected more often, yet the disease occurs in men, children and older adults. Presentation has peaks across age groups rather than one protected period. A substantial minority already have cirrhosis when first recognized, showing that mild or fluctuating biochemical disease may have been missed. Children may have autoimmune sclerosing cholangitis and require age-specific assessment. Older adults can respond to treatment but may carry greater bone, metabolic and infection vulnerability.
India lacks a single complete national AIH registry with uniform diagnostic verification. Apparent regional differences may therefore reflect which centres can perform IgG, immunofluorescence, MR cholangiography and expert liver histopathology. The clinically useful message is not a memorized prevalence: unexplained hepatocellular inflammation deserves evaluation regardless of demographic stereotype. Audits should count diagnostic delay, pretreatment biopsy, complete response, steroid exposure, relapse, infection, decompensation, transplant referral and loss to follow-up, with denominators and definitions stated.
Risk Factors
AIH arises from loss of immune tolerance in a genetically susceptible person, probably shaped by environmental and epigenetic influences. Associations with particular HLA backgrounds are population-dependent and are not routine diagnostic tests. A personal or family history of autoimmune thyroid disease, coeliac disease, type 1 diabetes, inflammatory bowel disease or another autoimmune disorder increases clinical awareness but neither proves nor excludes AIH. The patient did not cause the disease through diet, stress or inadequate hygiene, and it is not contagious.
Medicines, herbal preparations and supplements can produce drug-induced autoimmune-like hepatitis. Minocycline and nitrofurantoin are classic associations, while immune-checkpoint inhibitors and several other agents can create overlapping phenotypes. Record every exposure, start and stop date, dose, dechallenge and re-exposure rather than relying on the word herbal or natural. Autoantibodies and interface hepatitis may occur in drug injury, so neither alone distinguishes idiopathic AIH. Advanced fibrosis, relapse after immunosuppression withdrawal and persistent disease after the suspected drug is stopped can favour idiopathic disease, but specialist synthesis is required.
Once diagnosed, adverse-outcome risks include cirrhosis or acute severe presentation, delayed complete biochemical response, recurrent relapse, non-adherence, insufficient maintenance therapy and cumulative glucocorticoid toxicity. Viral hepatitis, tuberculosis, diabetes, obesity, alcohol-related injury and steatotic liver disease can coexist and modify treatment risk. Pregnancy is not a cause, but immune activity may change during gestation and postpartum flares are recognized. Barriers such as travel distance, unaffordable monitoring, fragmented prescriptions and unregulated alternative medicines are modifiable hazards in Indian care and should be addressed explicitly.
Diagnosis
History
Build a dated account of jaundice, dark urine, pale stool, pruritus, fatigue, anorexia, right-upper-quadrant discomfort, fever, weight change, abdominal swelling, bleeding, confusion and previous abnormal liver tests. Ask about viral exposure, transfusion, alcohol, metabolic risk, pregnancy, autoimmune symptoms and family disease. Reconcile prescription drugs, tuberculosis treatment, antibiotics, anticonvulsants, supplements and traditional remedies with timelines. Acute severe symptoms, encephalopathy or rapid worsening require immediate escalation rather than completion of an outpatient antibody panel.
Examination
Record mental state, temperature, pulse, blood pressure, weight and nutritional status. Seek jaundice, hepatomegaly, splenomegaly, ascites, oedema, bruising, muscle wasting, spider naevi and palmar erythema. Look for thyroid, coeliac, arthritic, cutaneous or other autoimmune clues without assuming they establish the liver diagnosis. A normal examination is compatible with biochemically active disease. Asterixis, hypotension, tense ascites or gastrointestinal bleeding suggests advanced or acute failure and changes urgency.
Investigations
Define the pattern and severity with ALT, AST, alkaline phosphatase, GGT, bilirubin, albumin, INR, full blood count, creatinine and IgG. Exclude hepatitis A when acute, hepatitis B, hepatitis C and other infections according to context; assess metabolic, vascular and hereditary alternatives. Test ANA and smooth-muscle antibody in adults, adding anti-LKM1, anti-LC1 or anti-SLA when appropriate and using laboratory-specific methods and cut-offs. About one fifth may be seronegative in some series. Ultrasound excludes obstruction and assesses portal hypertension; MRCP is indicated when cholestasis, inflammatory bowel disease or AIH-PSC is plausible. Liver biopsy is ordinarily central: expert histology assesses interface activity, plasma cells, rosettes, fibrosis, biliary injury and competing steatohepatitis or drug injury. Simplified or revised IAIHG scores support standardized reasoning but do not replace clinical judgment.
Differential Diagnosis
Viral hepatitis is the first major exclusion: acute HAV or HEV can resemble acute AIH, while HBV and HCV can create chronic inflammation and autoantibodies. Testing must match local epidemiology, timing and immune status. Drug-induced liver injury, including autoimmune-like injury, demands a complete exposure chronology. Metabolic dysfunction-associated steatotic liver disease and alcohol-related hepatitis may coexist with positive ANA; autoantibodies occur in a proportion of steatotic liver disease and should not trigger immunosuppression without a coherent phenotype. Wilson disease is particularly important in a young person or acute liver failure; hereditary haemochromatosis and alpha-1 antitrypsin deficiency enter appropriate differentials.
Cholestatic autoimmune disease changes management. PBC is suggested by sustained alkaline-phosphatase elevation, antimitochondrial antibody or PBC-specific ANA and small-duct injury. PSC is suggested by cholangiographic stricturing, inflammatory bowel disease or characteristic duct injury. AIH-PBC or AIH-PSC variant features are not diagnosed by casual coexistence of one antibody and one enzyme abnormality. The Paris criteria are useful for a classic AIH-PBC phenotype but can miss less typical cases; biopsy and the dominant histological pattern inform therapy. IgG4-related disease and biliary obstruction are additional cholestatic mimics.
Ischaemic hepatitis, Budd-Chiari syndrome, congestive hepatopathy, sepsis-associated injury and muscle-derived aminotransferase elevation require clinical context. Wilson-associated acute failure may have disproportionate bilirubin, haemolysis and relatively low alkaline phosphatase. In a treated patient with rising enzymes, reconsider non-adherence, under-dosing, drug toxicity, viral reactivation, steatotic disease and wrong diagnosis before declaring refractory AIH. A response to steroids supports immune activity but is unsafe as a stand-alone diagnostic test because other conditions may transiently improve or be dangerously masked.
Management
Hepatology should confirm disease activity, fibrosis and treatment indication. Most patients with active AIH require immunosuppression. Induction commonly uses prednisolone or prednisone, with azathioprine introduced or combined when safe; exact regimens vary with acute severity, cirrhosis, cytopenia and diagnostic certainty. The 2025 EASL guidance also recognizes mycophenolate mofetil as a first-line alternative with favourable efficacy and tolerability data, but its teratogenicity makes reproductive planning essential. Acute severe AIH needs admission, infection surveillance, frequent INR and bilirubin assessment and early transplant-centre communication if recovery is uncertain.
Monitor aminotransferases and IgG frequently during induction, then space reviews after stable complete biochemical response. Before calling treatment inadequate, verify adherence, weight-based exposure, interactions, diagnosis and active histology where needed. For azathioprine intolerance, mycophenolate is an established alternative; for true insufficient response, options may include optimized thiopurine or mycophenolate therapy and specialist use of tacrolimus or other agents. Evidence becomes progressively weaker beyond first-line therapy, and the 2026 INASL document emphasizes phenotype-specific management of difficult-to-treat disease. Rituximab or other biologics belong to expert centres, not routine escalation.
Maintenance is usually prolonged. Withdrawal is considered only after sustained biochemical remission and careful specialist assessment; relapse is common and requires prompt re-treatment. Cirrhosis care includes vaccination, nutrition, portal-hypertension assessment, bone health and hepatocellular-carcinoma surveillance where indicated. AIH-PBC may require UDCA plus immunosuppression according to the predominant process; AIH-PSC may need cholangiopathy surveillance in addition. Pregnancy should be planned in stable remission. Azathioprine and corticosteroids may be continued when benefits outweigh risks, whereas mycophenolate must be replaced well before conception under specialist guidance. Postpartum monitoring should intensify because flares occur.
Prescribing Information
Glucocorticoid treatment requires a written induction and taper plan linked to biochemical response, not an indefinite repeat prescription. Screen or assess for infection, diabetes, hypertension, osteoporosis, glaucoma, cataract and psychiatric vulnerability. Consider calcium, vitamin D and bone protection according to age, exposure and current guidance; vaccinate appropriately before intense immunosuppression when feasible. Fever, new respiratory symptoms or deterioration requires infection assessment, including tuberculosis where epidemiologically relevant, rather than automatic steroid escalation. Prolonged systemic corticosteroids must not be stopped abruptly because adrenal suppression and severe relapse are possible.
Before azathioprine, obtain full blood count, liver and renal profiles and assess thiopurine methyltransferase activity or genotype where available; normal testing does not remove the need for blood-count and liver-test surveillance. Explain nausea, pancreatitis, marrow suppression, infection and skin-cancer precautions. Thiopurine metabolites can help selected adherence or toxicity questions but are not universally available. Allopurinol profoundly changes thiopurine metabolism and must never be combined casually. In pregnancy, azathioprine may be used under specialist care; individual risk-benefit discussion replaces blanket discontinuation.
Mycophenolate causes gastrointestinal effects, cytopenia and infection and is teratogenic; effective contraception, preconception substitution and current product-specific washout advice are mandatory. Calcineurin inhibitors require trough levels, kidney function, blood pressure, glucose, electrolytes and interaction review. Budesonide undergoes high first-pass metabolism but is unsafe in cirrhosis or portal-systemic shunting and is not a rescue for acute severe disease. This guide deliberately avoids universal doses because formulation, body weight, severity, pregnancy and organ function alter safe prescribing. Every prescription needs indication, monitoring ownership, response target and toxicity plan.
When to Refer
Refer suspected AIH to gastroenterology or hepatology when aminotransferases remain unexplained, IgG is elevated, disease-specific antibodies are present, biopsy is needed or immunosuppression is being considered. Referral should include serial liver tests, INR, albumin, blood count, IgG, viral studies, imaging, pregnancy status and a complete medication and supplement history. Do not postpone referral merely because ANA or SMA is negative. Children require paediatric hepatology, particularly when autoimmune sclerosing cholangitis or inflammatory bowel disease is possible.
Same-day hospital assessment is required for encephalopathy, rapidly increasing jaundice, prolonged INR, hypoglycaemia, haemodynamic instability, acute kidney injury, sepsis, major gastrointestinal bleeding or new tense ascites. Acute severe AIH and acute liver failure need a centre able to provide intensive monitoring and transplant assessment. A trial of corticosteroid must not delay transplant listing when prognostic markers worsen. Decompensated cirrhosis, treatment failure despite verified adherence, recurrent severe flares and intolerable multi-agent toxicity justify transplant-centre or tertiary autoimmune-liver-disease input.
Multidisciplinary referral addresses specific hazards: maternal-fetal medicine for pregnancy; pharmacy for interactions and affordable monitoring; endocrinology or bone services for steroid complications; infectious diseases for tuberculosis, viral hepatitis or complex infection; and pathology review when biopsy and clinical phenotype conflict. Suspected AIH-PBC or AIH-PSC should be reviewed where hepatopathology and high-quality MRCP are available. The original team must continue interim monitoring and safety-netting until the specialist accepts care; a referral letter is not itself a transfer of clinical responsibility.
Red Flags
Confusion, drowsiness, asterixis, rapidly deepening jaundice, rising INR, hypoglycaemia, oliguria, severe vomiting, hypotension or bleeding may signal acute liver failure and require emergency admission. Aminotransferase height does not reliably measure remaining liver function: levels can fall while bilirubin, INR and encephalopathy worsen. Suspected acute severe AIH needs parallel exclusion of viral, toxic, vascular and metabolic causes plus early transplant-centre contact. Do not wait for antibody results or a perfect biopsy if the patient is deteriorating.
In chronic disease, haematemesis, melaena, new ascites, spontaneous bacterial peritonitis, fever with decompensation, progressive confusion, renal dysfunction and marked weight or muscle loss indicate cirrhosis complications. New focal liver lesions or an unexplained alpha-fetoprotein trend require the applicable hepatocellular-carcinoma pathway, not attribution to autoimmune activity. Severe cholestasis, recurrent cholangitis or dominant-duct concern may indicate PSC or obstruction. A mixed biochemical pattern with marked alkaline phosphatase, pruritus or AMA deserves reassessment for PBC overlap rather than simply increasing steroids.
Treatment emergencies include febrile neutropenia, profound thrombocytopenia, pancreatitis after azathioprine, severe infection, gastrointestinal bleeding, psychosis, uncontrolled hyperglycaemia or pregnancy during mycophenolate exposure. Rising creatinine or neurotoxicity on tacrolimus requires urgent review. Failure to improve may reflect non-adherence or inadequate exposure, but clinicians should explore cost, misunderstanding and adverse effects without blame. Repeated escalation without rechecking diagnosis, histology and drug delivery is itself a red flag. Any plan to stop maintenance therapy should include relapse monitoring and rapid access, because biochemical recurrence may precede symptoms.
Indian Clinical Context
Indian practice ranges from centres with expert hepatopathology, immunofluorescence and transplantation to facilities where IgG subclasses, anti-SLA, TPMT testing or MRCP are difficult to obtain. Resource limitation should change sequencing, not lower diagnostic honesty. Initial priorities are the pattern and severity of liver injury, INR and albumin, exclusion of treatable viral hepatitis, ultrasound for obstruction or portal hypertension, and early referral when biopsy or specialist therapy is required. Preserve original slides or blocks for expert review rather than repeating an invasive procedure solely because reporting language differs.
The 2026 INASL guidance is especially relevant to difficult-to-treat AIH in India, including acute disease, cirrhosis, drug-induced autoimmune-like hepatitis, overlap phenotypes, pregnancy, children and post-transplant recurrence. It complements rather than erases EASL or AASLD recommendations. Indian clinicians must account for tuberculosis, hepatitis B reactivation, endemic infections, nutrition, diabetes and access to serial laboratory monitoring before escalating immunosuppression. Screening tests need clinical interpretation; a positive latent-TB test does not explain every liver abnormality, while empirical steroids can mask active infection.
Azathioprine is generally more accessible than newer agents, but affordability is not safety if blood-count monitoring cannot occur. Mycophenolate and tacrolimus may be available unevenly and reproductive counselling is non-negotiable. Referral decisions should identify a realistically reachable centre and give the patient a written interim plan in an understood language. No robust national registry supplies a uniform Indian response rate, and international trials underrepresent several local constraints. Teams should document locally measured outcomes rather than advertise imported certainty.
NMC Competency Mapping
The NMC 2024 undergraduate curriculum provides foundations rather than an AIH prescribing licence. Physiology competency PY4.9 covers liver and gallbladder functions and interpretation of liver function tests. Pathology competencies in the liver sequence include mechanisms and morphology of hepatitis and cirrhosis, while PA24.6 addresses interpretation of liver-function and viral-hepatitis serology panels. These outcomes support understanding why aminotransferases, bilirubin, albumin and INR answer different clinical questions and why viral exclusion is mandatory before an autoimmune label.
General Medicine Topic 5 develops the clinical approach to liver disease. GM5.13 asks the learner to outline a diagnostic approach based on hyperbilirubinaemia, liver enzymes and function tests; GM5.15 addresses management of hepatitis, cirrhosis, portal hypertension and liver failure. Associated competencies cover history, abdominal examination, ascites, encephalopathy and appropriate investigations. AIH is a useful integrative case for immune mechanisms, serology, histopathology, rational immunosuppression, adverse-drug-reaction recognition and referral. It should be taught alongside viral hepatitis, drug injury, Wilson disease and biliary obstruction rather than as an antibody-recognition exercise.
At undergraduate level, learners should recognize the pattern, obtain a safe exposure history, order first-line exclusions, identify failure and refer. Liver-biopsy interpretation, selection of second-line immunosuppression, management of overlap disease, treatment withdrawal and transplant listing require supervised specialist training. NMC competency attainment must be assessed through cases, interpretation exercises and observed clinical skills; reading this draft cannot certify competence. Local university mapping should use the current official curriculum rather than copied legacy codes.
Key Exam Pearls for NEET PG
AIH classically produces a hepatocellular enzyme pattern, raised IgG, ANA or SMA positivity and interface hepatitis rich in lymphocytes and plasma cells. Anti-LKM1 is especially associated with a paediatric or younger phenotype, and anti-SLA can support otherwise seronegative disease. No antibody is individually diagnostic. The simplified IAIHG score uses autoantibodies, IgG, histology and viral exclusion; it supports classification but may underperform in acute severe, seronegative or overlap presentations. Liver biopsy remains central unless instability makes immediate management and transplant assessment the priority.
First-line induction is glucocorticoid-based, usually with a steroid-sparing strategy. Azathioprine is a traditional maintenance anchor; check marrow and liver toxicity and assess TPMT where available. Mycophenolate is an alternative for intolerance and is recognized by 2025 EASL guidance as a first-line alternative, but it is teratogenic. Budesonide is contraindicated in cirrhosis and is not used for acute severe disease. Complete biochemical response means normalization rather than partial improvement, and persistent abnormality warrants adherence, dose, diagnosis and histology review before second-line treatment.
Remember the variant pattern: PBC contributes cholestasis, AMA and florid duct lesions; PSC contributes cholangiographic strictures and inflammatory bowel disease; AIH contributes marked aminotransferases, IgG and interface hepatitis. Treat the dominant injury with specialist oversight. Pregnancy is safest in stable remission; corticosteroids and azathioprine may continue when indicated, whereas mycophenolate requires preconception replacement. Acute liver failure, decompensation or worsening despite appropriate therapy is a transplant question, not an invitation to endlessly increase immunosuppression.
Frequently Asked Questions
Can autoimmune hepatitis be diagnosed when ANA and smooth-muscle antibody tests are negative?
Yes. Seronegative AIH exists, so a negative initial antibody panel does not rule it out. The clinician reassesses assay method, IgG, additional antibodies, competing causes and liver histology. A simplified score may be less sensitive in this setting. Diagnosis and immunosuppression require hepatology judgment rather than a steroid trial used as a test.
Why is liver biopsy important when blood tests already suggest autoimmune hepatitis?
Biopsy provides evidence of interface activity, grades inflammation and fibrosis, and can reveal biliary injury, steatohepatitis, drug injury or another diagnosis. No histological feature is perfectly specific, so pathology is interpreted with serology and exclusions. In acute liver failure, biopsy timing must not delay stabilization or transplant-centre assessment.
Can a person with autoimmune hepatitis become pregnant while receiving treatment?
Many pregnancies are successful when disease is in stable remission and medicines are planned beforehand. Corticosteroids and azathioprine may be continued when clinically needed under specialist care. Mycophenolate is teratogenic and requires advance substitution and contraception advice. Maternal-fetal medicine and hepatology should monitor pregnancy and the postpartum flare period.
What should happen when aminotransferases do not normalize on first-line treatment?
First verify adherence, dose, interactions, treatment duration, infection and the diagnosis; assess whether histological activity or overlap disease is present. Intolerance and true insufficient response are different problems. Mycophenolate, tacrolimus or other escalation may be appropriate in selected patients, but evidence beyond standard therapy is weaker and expert-centre supervision is required.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic